{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HX575+epoetin+alfa",
    "query": {
      "intervention": "HX575 epoetin alfa"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 169,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HX575+epoetin+alfa&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T14:46:04.668Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02892149",
      "title": "Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia",
        "Dialysis-Dependent Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Vadadustat",
          "type": "DRUG"
        },
        {
          "name": "Darbepoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3554,
      "start_date": "2016-08",
      "completion_date": "2020-03-30",
      "has_results": true,
      "last_update_posted_date": "2022-06-28",
      "last_synced_at": "2026-09-27T14:46:04.668Z",
      "location_count": 127,
      "location_summary": "Huntsville, Alabama • Mesa, Arizona • Pine Bluff, Arkansas + 95 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02892149"
    },
    {
      "nct_id": "NCT01473407",
      "title": "A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Chronic Renal Failure"
      ],
      "interventions": [
        {
          "name": "Epoetin Hospira",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Epogen (Amgen)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 612,
      "start_date": "2012-01-31",
      "completion_date": "2014-02-11",
      "has_results": true,
      "last_update_posted_date": "2018-09-10",
      "last_synced_at": "2026-09-27T14:46:04.668Z",
      "location_count": 84,
      "location_summary": "Montgomery, Alabama • Tempe, Arizona • Alhambra, California + 65 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01473407"
    },
    {
      "nct_id": "NCT00334737",
      "title": "Darbepoetin Administration to Preterm Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infant, Newborn"
      ],
      "interventions": [
        {
          "name": "Darbepoetin Alfa Injection",
          "type": "DRUG"
        },
        {
          "name": "erythropoietin alfa injection",
          "type": "DRUG"
        },
        {
          "name": "sham injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Hour",
        "maximum_age": "49 Hours",
        "sex": "ALL",
        "summary": "1 Hour to 49 Hours"
      },
      "enrollment_count": 102,
      "start_date": "2006-06",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2019-02-04",
      "last_synced_at": "2026-09-27T14:46:04.668Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Ogden, Utah • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Ogden",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00334737"
    },
    {
      "nct_id": "NCT02174731",
      "title": "Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Roxadustat",
          "type": "DRUG"
        },
        {
          "name": "Epoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 2133,
      "start_date": "2014-07-01",
      "completion_date": "2018-09-26",
      "has_results": true,
      "last_update_posted_date": "2019-12-16",
      "last_synced_at": "2026-09-27T14:46:04.668Z",
      "location_count": 51,
      "location_summary": "Huntsville, Alabama • El Centro, California • Fairfield, California + 41 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02174731"
    },
    {
      "nct_id": "NCT00425126",
      "title": "Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Delayed Graft Function"
      ],
      "interventions": [
        {
          "name": "Epoetin Alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "West Penn Allegheny Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2007-02",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2010-05-27",
      "last_synced_at": "2026-09-27T14:46:04.668Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00425126"
    },
    {
      "nct_id": "NCT00858364",
      "title": "Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Anemia",
        "Cancer",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Darbepoetin alfa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2549,
      "start_date": "2009-07-17",
      "completion_date": "2017-06-07",
      "has_results": true,
      "last_update_posted_date": "2022-11-30",
      "last_synced_at": "2026-09-27T14:46:04.668Z",
      "location_count": 277,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00858364"
    },
    {
      "nct_id": "NCT03029208",
      "title": "Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anaemia"
      ],
      "interventions": [
        {
          "name": "Daprodustat",
          "type": "DRUG"
        },
        {
          "name": "Darbepoetin alfa",
          "type": "DRUG"
        },
        {
          "name": "Iron therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 312,
      "start_date": "2017-05-11",
      "completion_date": "2020-09-24",
      "has_results": true,
      "last_update_posted_date": "2021-10-20",
      "last_synced_at": "2026-09-27T14:46:04.668Z",
      "location_count": 36,
      "location_summary": "Anaheim, California • Cerritos, California • Escondido, California + 31 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "La Palma",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03029208"
    },
    {
      "nct_id": "NCT00520468",
      "title": "Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Erythropoietin",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporin A",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 15,
      "start_date": "2004-06",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2012-08-07",
      "last_synced_at": "2026-09-27T14:46:04.668Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00520468"
    },
    {
      "nct_id": "NCT00146562",
      "title": "Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Stage I Breast Cancer",
        "Stage II Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Darbepoetin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harold J. Burstein, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2003-07",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2023-08-02",
      "last_synced_at": "2026-09-27T14:46:04.668Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Lowell, Massachusetts • Peabody, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Lowell",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00146562"
    },
    {
      "nct_id": "NCT00286182",
      "title": "Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Erythropoietin alpha",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mathew S. Maurer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2007-07",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2017-03-10",
      "last_synced_at": "2026-09-27T14:46:04.668Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00286182"
    }
  ]
}